Doctors have successfully treated an infant with a rare childhood leukemia using a targeted therapy approved for adults with inoperable liver cancer and advanced kidney cancer. The decision to use the drug, sorafenib, was made after pathologists identified a unique mutation of two genes being fused together instead of on separate chromosomes.